Preterm Births In US Climb To 10.5%, Annual Report Card Finds
The March of Dimes’ latest report card gives the U.S. an overall D+ grade for its rate of preterm births, which can lead to infant death and have negative long-term effects on child development.
NPR:
A Nonprofit Says Preterm Births Are Up In The U.S. — And It's Not A Partisan Issue
Preterm births are a leading cause of infant deaths and can have long-term effects on a child's health and development. And, according to a new report, they're on the rise. On Tuesday, the nonprofit March of Dimes released its 2022 Report Card, which grades the whole country as well as individual states, Washington, D.C., and Puerto Rico on measures related to the health of moms and babies. (Treisman, 11/15)
CNN:
US Gets D+ Grade For Rising Preterm Birth Rates, New Report Finds
Taking an in-depth look at premature births, the new report found that the US preterm birth rate rose to 10.5% last year, representing an increase of 4% since 2020 and the worst national rate since March of Dimes started tracking this data in 2007, based on its new calculation system. “This is actually a 15-year high in the preterm birth rate in this country,” said Dr. Zsakeba Henderson, senior vice president and interim chief medical and health officer at March of Dimes. (Howard, 11/15)
Bloomberg Law:
Maternal Health Backers Seek To Add Bill To Year-End Package
A pair of House Democrats are leading a year-end push to bolster maternal health as part of the next spending bill.Democratic Reps. Robin Kelly (Ill.) and Lauren Underwood (Ill.) are gathering support for a package of maternal health bills (H.R. 959) that includes mandatory year-long Medicaid coverage after someone gives birth. (Ruoff and Baumann, 11/15)
In updates on the baby formula shortage —
Reuters:
FDA To Review Baby Formula Production Rules To Prevent Bacterial Illness
The U.S. health regulator said on Tuesday it would review guidance and rules about manufacturing infant formula as part of its strategy to prevent bacterial illness similar to Abbott Laboratories' products this year. The Food and Drug Administration will also consider whether to establish a dedicated group of investigators and realign staff across two of its divisions to better support regulatory oversight of infant formula, among other measures, it said. (11/15)
